Chronic lymphocytic leukaemia (CLL) is the most common form of adult leukaemia in the Western world.1,2 In the UK, CLL accounts for 1% of all new cancer cases and 38% of all leukaemias.3
The new CLL Knowledge Centre provides healthcare professionals with important information to aid the treatment and management of patients with the disease. Content is arranged within three main areas: ‘Disease awareness’, ‘Events’ and ‘Resources’.
Healthcare professionals will find sections on pathophysiology, signs and symptoms of CLL, diagnosis, prognosis, treatment, management, an upcoming events calendar and useful external links.
We are conducting a short survey regarding educational needs of healthcare professionals in relation to chronic lymphocytic leukaemia (CLL) and other haematological malignancies.
The questions will take approximately 5-10 minutes of your time to complete and your input will be much appreciated.
Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood. 2013 Nov 28;122(23):3723-34.
Gibson J, Iland HJ, Larsen SR, Brown CM, Joshua DE. Leukaemias into the 21st century. Part 2: the chronic leukaemias. Intern Med J. 2013 May;43(5):484-94.
Prostate cancer is the third most frequently diagnosed cancer in Europe and the most common cancer among European men,1 making it a major cause of morbidity. Risk factors for prostate cancer include, increasing age, genetic susceptibility, glucose intolerance and environmental factors.2
The Prostate Cancer Learning Hub has been designed with the busy healthcare professional in mind. The resource conveniently organises a range of up-to-date education content, reference materials and decision support tools, all focussing on prostate cancer.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-1403. EUCAN fact sheet. Estimated incidence, mortality & prevalence, 2012.
Tewari R, Rajender S, Natu SM et al. Diet, obesity, and prostate health: are we missing the link? J Androl 2012;33:763-776.
Soft Tissue Sarcomas (STS) are malignant (cancerous) tumors that develop in tissues which connect, support, or surround other structures and organs of the body. Muscles, tendons (bands of fiber that connect muscles to bones), fibrous tissues, fat, blood vessels, nerves, and synovial tissues are types of soft tissue.
Management of soft tissue sarcoma depends on the stage of disease and histological subtype.1 Surgery is the mainstay of treatment for patients with localised disease and is often curative. However, as recurrence is likely to occur when tumour cells remain after surgery, adjuvant radiotherapy is often also considered, especially for patients with intermediate or high-grade tumours. Radiotherapy, uses high energy rays to help cure cancers, is also often administered for patients in whom surgery is inappropriate or who decline surgery.1
For soft tissue sarcomas, the specialist healthcare professional may recommend radiotherapy to shrink sarcomas before surgery, help stop the sarcoma returning after surgery, to help slow the growth rate of advanced sarcomas and help relieve symptoms.
Discover classification of sarcomas by histopathology, look at prevalence and more by visiting the The Soft Tissue Sarcoma Knowledge Centre.
. Clark MA, Fisher C et al. (2005) “Soft-tissue sarcomas in adults.” N Engl JMed 353(7): 701–11.
The Anti-Infectives Knowledge Network – Clostridium difficile infection (AIKN-CDI), an initiative by Astellas Pharma EMEA, shares the expertise and experience of thought leaders in the area of anti-infectives.
This educational resource is sponsored by Astellas Pharma EMEA and assembles the expertise of key thinkers in the area of anti-infectives with a focus on invasive fungal infections.
Ensure you return often to make the most of regular updates to this resource including congress highlights, industry reports, policy changes, clinical guidelines and downloadable materials (e.g. presentation slides) from major medical events.
The congresses section has been updated with a report from the ‘Integrating Critical Care and Haemato-oncology’ meeting held in Berlin, November 2014. Experts gathered to share opinion and debate on the changing nature of care for haemato-oncology patients requiring critical care. View this report for free here.
Respiratory Medicine & Allergy: Non granuloma interstitial lung disease
Richard Leach, Consultant Respiratory Physicians, Guy's and St Thomas' NHS Foundation Trust, London, UK
Case History A 44-year-old black lady presented with an eight-month history of tiredness, rapidly progressive breathlessness and bilateral interstitial, perihilar shadowing on a chest radiograph (CXR). Non-caseating granulomas were detected in transbronchial biopsies consistent with a diagnosis of sarcoidosis.
Elizabeth Hadley, Consultant Respiratory and General Physician, Barking, Havering and Redbridge Hospitals University NHS Trust, London, UK
Case History A 24-year-old woman was seen in the chest clinic with an eight-week history of cough with occasional sputum, fever and malaise. She also described an occasional nagging pain under her sternum and palpitations.
4 days ago -
A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells.
Temozolomide (TMZ) is an oral alkylating chemotherapeutic agent that prolongs the survival of patients with glioblastoma (GBM). Despite that high TMZ potential, progression of disease and recurrence ...
This guideline updates and replaces NICE clinical guideline CG27 (published June 2005). It offers..
... evidence-based advice on the recognition of and referral for suspected cancer in children, young people and adults.
This guideline covers the recognition and selection for referral or investigation in primary care of people of all ages, including children and young people, who may have cancer. Although we have used the terms 'men' and 'women' for recommendations on gender-related cancers, these recommendations also extend to people who have changed or are in the process of changing gender, and who retain the relevant organs.
The guideline aims to help people understand what to expect if they have symptoms that may suggest cancer. It should also help those in secondary care to understand which services should be provided for people with suspected cancer. Finally, these recommendations are recommendations, not requirements, and they are not intended to override clinical judgement.
The recommendations in this guideline have been organised into 3 separate sections to help clinicians find the relevant information easily. In the first, the recommendations are organised by cancer site. There is a section covering patient support, safety netting and the diagnostic process. Then, for those wanting to find recommendations on specific symptoms and primary care investigations, the recommendations are in a section organised by symptoms and investigation findings.
This activity is intended for oncologists, urologists, and other clinicians who treat men with metastatic castration-resistant prostate cancer (mCRPC). The goal of this activity is to improve the knowledge and...
This activity is intended for oncologists, urologists, and other clinicians who treat men with castration-resistant prostate cancer (CRPC). The goal of this activity is to improve the knowledge on the...
Explore the Obesity Learning Hub containing an EACCME-accredited CME series, Knowledge Centre, clinical media library, news and journal articles, events information, patient guides, and more – available free of charge